Chronic Pain in Senior Cats — Management Guide

Comprehensive, practical guide to recognizing and managing chronic pain in senior cats — causes, subtle signs, diagnostics, drug options (NSAIDs, gabapentin, buprenorphine, Solensia), environment changes, and monitoring.

Quick Overview

• What it is: Chronic pain in senior cats most often arises from osteoarthritis (degenerative joint disease), dental disease, chronic soft-tissue or neurologic disorders, and cancer. Pain is persistent or recurrent and can be subtle.
• Who’s at risk: Older cats (generally >8–10 years), overweight cats, cats with prior joint injury, some purebreds with conformational predisposition (see below).
• Prognosis: Chronic pain is frequently manageable but often progressive. With appropriate multimodal therapy and monitoring, many cats have markedly improved mobility and quality of life.

Pathophysiology (explained simply)

Chronic pain is different from short-term (acute) pain. In osteoarthritis (OA), cartilage wears away and the joint becomes inflamed. Nerve endings in the joint become sensitized, so ordinary movement causes pain. Over time, central nervous system changes can maintain a heightened pain state (central sensitization). Persistent pain affects behavior, appetite, sleep and mobility.

Breed-specific risk factors and prevalence

• Prevalence: Studies estimate radiographic OA in older cats ranges from 40–90% depending on population and diagnostic criteria; clinically apparent OA is lower but still common in senior cats.
• Breed risk factors: Certain breeds with conformational or genetic predispositions are over-represented for degenerative joint disease (e.g., Maine Coon may have higher risk of hip/elbow disease; Bengals and other active breeds may show earlier signs after injury). However, OA is widespread in mixed-breed and purebred cats alike.
• Other risk factors: Obesity, prior trauma, metabolic disease, and certain congenital joint abnormalities increase lifetime risk.

Cats hide pain. Look for subtle, progressive changes rather than dramatic limping.

Common signs

• Decreased activity, reluctance to jump up or down
• Reduced play, hiding more, sleeping more
• Difficulty using the litterbox (inappropriate elimination, sitting too long to enter/exit the box)
• Stiffness on rising, slower gait, mild to intermittent lameness
• Decreased grooming leading to matted coat
• Irritability or changes in interaction with owners
• Altered posture – hunched back, limb guarding

• Mild (early): Slight stiffness after rest, less jumping, subtle behavior change.
• Moderate: Clear reluctance to jump, occasional mobility or litterbox issues, reduced social play.
• Severe: Marked mobility loss, persistent pain signs, weight loss, poor grooming, marked change in daily function.

Treatment options — multimodal approach

Goal: Reduce pain, improve function, and minimize side effects. Combine drug therapy, local measures, physical rehabilitation and environmental changes.

Medical treatment

• NSAIDs (nonsteroidal anti-inflammatory drugs)

• Gabapentin

• Buprenorphine

• Solensia (frunevetmab) — anti-NGF monoclonal antibody

• Other medical options

Surgical and procedural options

• Surgery: Rarely performed for OA in cats but may be indicated for certain joint problems (fracture repair, luxation, tumor removal). Joint replacement is uncommon in cats but may be considered in specialist centers.
• Intra-articular therapy: Corticosteroid injections or other joint injections can be considered selectively by specialists.

• Physical rehabilitation/physiotherapy: Therapeutic exercises, controlled walking, hydrotherapy, massage, and laser therapy can improve mobility and reduce pain.
• Acupuncture: Many cats respond favorably; evidence is variable but helpful as adjunctive therapy for some.
• Environmental/enrichment changes (see separate section below).

• Regular rechecks: Reassessment 2–4 weeks after starting or changing therapy to evaluate response, then every 3–6 months or sooner if concerns. Use the same pain questionnaire (FMPI) and photos/videos to track progress.
• Lab monitoring: For cats on NSAIDs or long-term medications, repeat CBC/chemistry and urinalysis ~1–2 weeks after starting, then at 1–3 months and every 3–6 months thereafter depending on risk and stability.
• Adjusting therapy: Titrate to effect and side effects. Multimodal therapy often means combining an NSAID (if safe) with gabapentin and/or Solensia. If one modality fails or causes side effects, discuss alternatives with your vet or a pain specialist.

• Chronic pain due to OA is generally progressive but can be substantially improved. With appropriate multimodal therapy, many cats regain meaningful function and comfort.
• Quality of life decisions: Use objective measures (activity, appetite, grooming, litterbox use) and validated scales to judge improvement. Palliative and end-of-life planning should involve honest discussions with your veterinarian when medical management no longer maintains an acceptable quality of life.

• Manage weight: Even modest weight loss (5–10%) reduces joint stress and improves mobility.
• Modify the environment:

• Enrichment: Short, gentle play sessions; food puzzles to encourage low-impact activity.
• Grooming: Help brush or clip matted fur if the cat struggles to groom.
• Medication routines: Use pill alternatives (transmucosal or injectable) if pill administration is stressful; coordinate monthly clinic visits for Solensia if appropriate.

• Sudden worsening of pain or acute lameness, especially after trauma.
• New reluctance to eat, severe vomiting or diarrhea after starting medications.
• Signs of neurologic deterioration (weakness, collapse, inability to stand).
• Marked change in behavior suggesting severe pain (aggression, severe hiding, vocalization), or inability to use litterbox for 24+ hours.

• Never give over-the-counter human NSAIDs to cats — they are frequently fatal.
• Always check renal function before starting NSAIDs and repeat tests per your vet’s guidance.
• Dosing specifics: Your veterinarian will prescribe exact doses based on brand, formulation, and your cat’s weight and medical status. Use medications exactly as directed.

• American Association of Feline Practitioners (AAFP) / International Society of Feline Medicine guidance, and AAHA pain management resources — for general pain recognition and multimodal care.
• Peer-reviewed trials and product information for frunevetmab (Solensia) show statistically significant owner-assessed improvements in feline OA pain compared with placebo (Zoetis/Solensia product literature; U.S. approval materials).
• Clinical reviews and veterinary pharmacology resources on NSAID safety in cats and the role of gabapentin and opioids in feline pain management.

This guide is for educational purposes. Always consult your veterinarian for diagnosis and treatment.

References and further reading

• Zoetis. Solensia (frunevetmab) product information and prescribing information. https://www.zoetisus.com/products/solensia
• AAFP/ISFM/AAHA resources on feline pain and analgesia.
• Veterinary peer-reviewed literature on feline OA, gabapentin use, and NSAID safety monitoring.

Frequently Asked Questions